Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis

Diagnostic Molecular Pathology

Volumn 12, Issue 2, 2003, Pages 63-70

  Best, Carolyn J M ^a   Leiva, Isabel M ^a,b   Chuaqui, Rodrigo F ^a   Gillespie, John W ^a,c   Duray, Paul H ^a   Murgai, Meera ^a   Zhao, Yingdong ^c   Simon, Richard ^c   Kang, Jason J ^c   Green, Jeffrey E ^c   Bostwick, David G ^d   Linehan, W Marston ^a   Emmert Buck, Michael R ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c MAYO CLINIC   (United States)

^d BOSTWICK LABORATORIES   (United States)

^e Laboratory of Pathology   (United States)

Author keywords

Aggressive prostate cancer; cDNA microarrays; Gene expression profiling

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANK SUM TEST;

ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; DNA, COMPLEMENTARY; DNA, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 0038102387     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200306000-00001     Document Type: Article

References (40)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res2001;61:5692-6.
3. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
4. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
5. Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared with benign prostatic hyperplasia. J Urol 2001;166:2171-7.
6. Welsh JB, Sapinoso LM, Su A, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
7. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-80.
8. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer. Cancer Cell 2002;1:203-9.
9. Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-33.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
11. Khan J, Simon R, Bittner M, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998;58:5009-13.
12. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-8.
13. Puskas LG, Zvara A, Hackler L, et al. Production of bulk amounts of universal RNA for DNA microarrays. Biotechniques 2002;33:898-900.
14. Luo J, Dunn T, Ewing C, et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002;51:189-200.
15. Luo JH, Yu YP, Cieply K, et al. Gene expression analysis of prostate cancer. Mol Carcinog 2002;33:25-35.
16. Chuaqui RF, Bonner RF, Best CJM, et al. Validation of array results: quantitative methods, tissue arrays and layered expression scanning. Nature Genet 2002;32(S):509-14.
17. Canada AT, Roberson KM, Vessella RL, et al. Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Biochem Pharmacol 1996;51:87-90.
18. Tomita K, van Bokhoven A, Jansen CFJ, et al. Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alphacatenin. Biochem Biophys Res Commun 2000;267:870-4.
19. Degen WG, van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152:805-13.
20. Choi S, Kobayashi M, Wang J, et al. Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis 2000;18:45-50.
21. Strnad J, Hamilton AE, Beavers LS, et al. Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 1989;49:314-7.
22. Calabrese G, Crescenzi C, Morizio E, et al. Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 2001; 92:164-5.
23. Castagnetta LA, Carruba G, Traina A, et al. Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology 1997;138:4876-82.
24. Fan C, Stendahl U, Stjernberg N, et al. Association between orosomucoid types and cancer. Oncology 1995;52:498-500.
25. Hollinshead AC, Chuang CY, Cooper EH, et al. Interrelationship of prealbumin and alpha-1 acid glycoprotein in cancer patient sera. Cancer 1977;40:2993-8.
26. Dube JY, Paradis G, Tetu B, et al. Synthesis of alpha 1-acid glycoprotein by the human prostate. Prostate 1989;15:251-8.
27. Lee SY, Lim JW, Kim Y-M. Effect of alphal-acid glycoprotein expressed in cancer cells on malignant characteristics. Mol Cells 2001;11:341-5.
28. Evdokiou A, Webb GC, Peters GB, et al. Localization of the human growth arrest-specific gene (GAS1) to chromosome bands 9q21.3-q22, a region frequently deleted in myeloid malignancies. Genomics 1993;18:731-3.
29. Bettuzzi S, Scorcioni F, Astancolle S, et al. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40 immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002;21:4328-34.
30. Wikman H, Kettunen E, Seppanen JK, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002;21:5804-13.
31. Smid-Koopman E, Blok LJ, Chadha-Ajwani S, et al. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer 2000;83:246-51.
32. Huang H, Colella S, Kurrer M, et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 2000;60:6868-74.
33. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
34. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet 1999;21:103-7.
35. Gong MC, Latouche JB, Krause A, et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-7.
36. Cole KA, Krizman DB, Emmert-Buck MR. The genetics of cancer-a 3D model. Nature Genet 1999;21:38-41.
37. Paweletz CP, Ornstein DK, Roth M, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-7.
38. Byrne JA, Tomasetto C, Garnier JM, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995;55:2896-903.
39. Jensen DE, Rauscher FJ, III. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann NY Acad Sci 1999;886:191-4.
40. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994;54:1941s-3.